Who makes MK-8266 TID, 2.4 mg?

MK-8266 TID, 2.4 mg is developed by Merck Sharp & Dohme LLC.

What development phase is MK-8266 TID, 2.4 mg in?

MK-8266 TID, 2.4 mg is in Phase 1.

What are the side effects of MK-8266 TID, 2.4 mg?

Common side effects include Headache, Supraventricular tachycardia, Ventricular tachycardia, Ear pain, Lacrimation increased, Application site pruritus.

Last reviewed 2026-05-14 · How we verify

MK-8266 TID, 2.4 mg

Merck Sharp & Dohme LLC · Phase 1 active Small molecule Quality 15/100

At a glance

Generic name	MK-8266 TID, 2.4 mg
Also known as	MK-8266
Sponsor	Merck Sharp & Dohme LLC
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

Headache
Supraventricular tachycardia
Ventricular tachycardia
Ear pain
Lacrimation increased
Application site pruritus
Post procedural haematoma
Muscle twitching
Presyncope
Oropharyngeal pain
Pruritus
Skin irritation

Key clinical trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8266 in Hypertensive Men (MK-8266-002) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MK-8266 TID, 2.4 mg CI brief — competitive landscape report
MK-8266 TID, 2.4 mg updates RSS · CI watch RSS
Merck Sharp & Dohme LLC portfolio CI